other
GLP-1 receptor agonist molecule first approved for type 2 diabetes, later dosed higher for obesity; cited in the cluster's kidney and liver outcome trials.
No evidence-backed relationships are recorded.
A 2026 JAMA Surgery analysis shows surgical obesity care losing a third of its volume in two years. The spend has not vanished; it has moved to the pharmacy benefit, where coverage decides who gets treated.
Reality
Enveda's ENV-308, a mimic of the exercise hormone Lac-Phe, was safe and well tolerated in its first human trial. The muscle-sparing weight-maintenance pitch is still a hypothesis.
Reality
A small semaglutide trial reported endocrine gains, not just weight loss, in a condition affecting one in eight women. Fortune reports insurers are already putting up barriers.
Reality
Measured US adult obesity sat at 40.3 percent across 2013 to 2023 while severe obesity rose from 7.7 to 9.7 percent. The programs did not bend the line, and benefits committees now own the question.
Reality